CD47 and neoplasm: Due to cellular IAPs’ simultaneous role in regulating NFκB signaling, treatment with IAP antagonists sensitizes tumor cells to apoptotic signals while increasing alternative NFκB signaling in T cells and the tumor microenvironment in promising ways that may support immunotherapy for MM (Chesi et al. 2016, Gu et al. 2021, Roehle et al. 2021).